Gut Microbiota–Dependent Trimethylamine N-Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes. Issue 9 (September 2018)

• Record Type: Journal Article
• Authors: Haghikia, Arash; Li, Xinmin S.; Liman, Thomas G.; Bledau, Nils; Schmidt, David; Zimmermann, Friederike; Kränkel, Nicolle; Widera, Christian; Sonnenschein, Kristina; Haghikia, Aiden; Weissenborn, Karin; Fraccarollo, Daniela; Heimesaat, Markus M.; Bauersachs, Johann; Wang, Zeneng; Zhu, Weifei; Bavendiek, Udo; Hazen, Stanley L.; Endres, Matthias; Landmesser, Ulf
• Is Part Of: Arteriosclerosis, thrombosis, and vascular biology. Volume 38:Issue 9(2018)
• Publication Date: 2018-09
• Subjects: choline -- gut microbiome -- myocardial infarction -- risk factors -- stroke -- thrombosis; Arteriosclerosis -- Periodicals; Thrombosis -- Periodicals; Blood-vessels -- Pathophysiology -- Periodicals; Electronic journals; 616.13
• DOI: 10.1161/ATVBAHA.118.311023
• Languages: English
• ISSNs: 1079-5642

Abstract

Abstract : Objective—: Gut microbiota–dependent metabolites, in particular trimethylamine N -oxide (TMAO), have recently been reported to promote atherosclerosis and thrombosis. Here, we examined for the first time the relation of TMAO and the risk of incident cardiovascular events in patients with recent first-ever ischemic stroke in 2 independent prospective cohorts. Moreover, the link between TMAO and proinflammatory monocytes as a potential contributing factor for cardiovascular risk in stroke patients was studied. Approach and Results—: In a first study (n=78), higher TMAO plasma levels were linked with an increased risk of incident cardiovascular events including myocardial infarction, recurrent stroke, and cardiovascular death (fourth quartile versus first quartile; hazard ratio, 2.31; 95% CI, 1.25–4.23; P <0.01). In the second independent validation cohort (n=593), high TMAO levels again heralded marked increased risk of adverse cardiovascular events (fourth quartile versus first quartile; hazard ratio, 5.0; 95% CI, 1.7–14.8; P <0.01), and also after adjustments for cardiovascular risk factors including hypertension, diabetes mellitus, LDL (low-density lipoprotein) cholesterol, and estimated glomerular filtration rate (hazard ratio, 3.3; 95% CI, 1.2–10.9; P =0.04). A significant correlation was also found between TMAO levels and percentage of proinflammatory intermediate CD14 ++ CD16 + monocytes ( r =0.70; P <0.01). Moreover, in mice fed a diet enriched with choline to increase TMAO synthesis, levels of proinflammatory murine Ly6C high monocytes were higher than in the chow-fed control group (choline: 9.2±0.5×10 3 per mL versus control: 6.5±0.5×10 3 per mL; P <0.01). This increase was abolished in mice with depleted gut microbiota (choline+antibiotics: 5.4±0.7×10 3 per mL; P <0.001 versus choline). Conclusions—: The present study demonstrates for the first time a graded relation between TMAO levels and the risk of subsequent cardiovascular events in patients with recent prior ischemic stroke. Our data support the notion that TMAO-related increase of proinflammatory monocytes may add to elevated cardiovascular risk of patients with increased TMAO levels. Abstract : Supplemental Digital Content is available in the text.